Compare Biocon Ltd with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SUN PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SUN PHARMA BIOCON /
SUN PHARMA
 
P/E (TTM) x 22.8 21.1 108.2% View Chart
P/BV x 3.0 2.5 122.3% View Chart
Dividend Yield % 0.4 0.6 59.2%  

Financials

 BIOCON    SUN PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
SUN PHARMA
Mar-19
BIOCON /
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188679 175.0%   
Low Rs305375 81.2%   
Sales per share (Unadj.) Rs68.7121.1 56.7%  
Earnings per share (Unadj.) Rs7.613.4 56.5%  
Cash flow per share (Unadj.) Rs14.020.7 67.5%  
Dividends per share (Unadj.) Rs1.002.75 36.4%  
Dividend yield (eoy) %0.10.5 25.7%  
Book value per share (Unadj.) Rs86.3172.6 50.0%  
Shares outstanding (eoy) m600.002,399.26 25.0%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.4 249.7%   
Avg P/E ratio x98.939.4 250.9%  
P/CF ratio (eoy) x53.425.5 209.7%  
Price / Book Value ratio x8.63.1 283.1%  
Dividend payout %13.220.6 64.4%   
Avg Mkt Cap Rs m447,9001,264,650 35.4%   
No. of employees `0006.117.5 35.1%   
Total wages/salary Rs m9,31159,671 15.6%   
Avg. sales/employee Rs Th6,705.816,608.1 40.4%   
Avg. wages/employee Rs Th1,514.23,409.6 44.4%   
Avg. net profit/employee Rs Th736.91,833.8 40.2%   
INCOME DATA
Net Sales Rs m41,234290,659 14.2%  
Other income Rs m2,06210,255 20.1%   
Total revenues Rs m43,296300,914 14.4%   
Gross profit Rs m8,29163,076 13.1%  
Depreciation Rs m3,85117,533 22.0%   
Interest Rs m6155,553 11.1%   
Profit before tax Rs m5,88750,246 11.7%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m1,5696,009 26.1%   
Profit after tax Rs m4,53132,093 14.1%  
Gross profit margin %20.121.7 92.7%  
Effective tax rate %26.712.0 222.9%   
Net profit margin %11.011.0 99.5%  
BALANCE SHEET DATA
Current assets Rs m41,486310,692 13.4%   
Current liabilities Rs m21,413173,396 12.3%   
Net working cap to sales %48.747.2 103.1%  
Current ratio x1.91.8 108.1%  
Inventory Days Days6499 64.6%  
Debtors Days Days94112 84.4%  
Net fixed assets Rs m50,661232,477 21.8%   
Share capital Rs m3,0002,399 125.0%   
"Free" reserves Rs m48,808411,691 11.9%   
Net worth Rs m51,808414,091 12.5%   
Long term debt Rs m17,89815,226 117.5%   
Total assets Rs m99,897646,938 15.4%  
Interest coverage x10.610.0 105.2%   
Debt to equity ratio x0.30 939.5%  
Sales to assets ratio x0.40.4 91.9%   
Return on assets %5.25.8 88.5%  
Return on equity %8.77.8 112.8%  
Return on capital %9.610.2 94.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05866,025 18.3%   
Fx outflow Rs m7,34838,610 19.0%   
Net fx Rs m4,71027,415 17.2%   
CASH FLOW
From Operations Rs m6,62121,965 30.1%  
From Investments Rs m-6,840-6,813 100.4%  
From Financial Activity Rs m-2,397-27,305 8.8%  
Net Cashflow Rs m-2,612-8,442 30.9%  

Share Holding

Indian Promoters % 40.4 63.7 63.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.1 163.7%  
FIIs % 10.7 23.0 46.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.3 239.8%  
Shareholders   109,995 133,026 82.7%  
Pledged promoter(s) holding % 0.0 0.5 7.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Nov 18, 2019 (Close)

TRACK BIOCON

BIOCON - PIRAMAL ENTERPRISES COMPARISON

COMPARE BIOCON WITH

MARKET STATS